Dexin Zhang1, Guizuo Wang1, Dong Han1, Yonghong Zhang1, Jing Xu1, Jiamei Lu1, Shaojun Li1, Xinxing Xie1, Lu Liu1, Lei Dong1, Manxiang Li2. 1. Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, China. 2. Department of Respiratory Medicine, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, China. Electronic address: manxiangli@hotmail.com.
Abstract
AIMS: Our previous study has indicated that activation of PPAR-γ inhibits the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) in vitro through inducing the expression of heme oxygenase-1 (HO-1), which in turn up-regulates the p21(WAF1) expression. In the present study, we intended to determine whether similar mechanisms have been involved in activation of PPAR-γ inhibition of development of rat PAH model. MATERIAL AND METHODS: Rat pulmonary arterial hypertension (PAH) model was established by subcutaneous injection of monocrotaline (MCT). Rosiglitazone was administered to activate PPAR-γ. Zinc protoporphyria IX (ZnPP-IX), was used to confirm the role of HO-1 in mediating PPAR-γ function. Parameters including the right ventricle systolic pressure (RVSP), the right ventricular hypertrophy (RVH) and the percentage of medial wall thickness were used to evaluate the development of PAH. Immunoblotting was used to determine the expression of HO-1 and p21(WAF1). KEY FINDINGS: Rosiglitazone significantly decreased the RVSP and inhibited the RVH in MCT-induced rat PAH model, and partially inhibited the pulmonary vascular remodeling. These effects were coupled with the sequential increase of HO-1 and p21(WAF1) expressions by rosiglitazone. SIGNIFICANCE: Activation of PPAR-γ benefits PAH by inhibiting proliferation of PASMCs and reducing pulmonary vascular remodeling. The present study suggests that enhancing PPAR-γ activity might have potential value in clinical treatment of PAH.
AIMS: Our previous study has indicated that activation of PPAR-γ inhibits the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) in vitro through inducing the expression of heme oxygenase-1 (HO-1), which in turn up-regulates the p21(WAF1) expression. In the present study, we intended to determine whether similar mechanisms have been involved in activation of PPAR-γ inhibition of development of rat PAH model. MATERIAL AND METHODS:Ratpulmonary arterial hypertension (PAH) model was established by subcutaneous injection of monocrotaline (MCT). Rosiglitazone was administered to activate PPAR-γ. Zinc protoporphyria IX (ZnPP-IX), was used to confirm the role of HO-1 in mediating PPAR-γ function. Parameters including the right ventricle systolic pressure (RVSP), the right ventricular hypertrophy (RVH) and the percentage of medial wall thickness were used to evaluate the development of PAH. Immunoblotting was used to determine the expression of HO-1 and p21(WAF1). KEY FINDINGS:Rosiglitazone significantly decreased the RVSP and inhibited the RVH in MCT-induced rat PAH model, and partially inhibited the pulmonary vascular remodeling. These effects were coupled with the sequential increase of HO-1 and p21(WAF1) expressions by rosiglitazone. SIGNIFICANCE: Activation of PPAR-γ benefits PAH by inhibiting proliferation of PASMCs and reducing pulmonary vascular remodeling. The present study suggests that enhancing PPAR-γ activity might have potential value in clinical treatment of PAH.
Authors: Justine I Blum; Kaiser M Bijli; Tamara C Murphy; Jennifer M Kleinhenz; C Michael Hart Journal: Am J Med Sci Date: 2016-04-04 Impact factor: 2.378
Authors: Samantha M Yeligar; Bum-Yong Kang; Kaiser M Bijli; Jennifer M Kleinhenz; Tamara C Murphy; Gloria Torres; Alejandra San Martin; Roy L Sutliff; C Michael Hart Journal: Am J Respir Cell Mol Biol Date: 2018-05 Impact factor: 6.914
Authors: Lei Yang; Di Yu; Ran Mo; Jiru Zhang; Hu Hua; Liang Hu; Yu Feng; Song Wang; Wei-Yan Zhang; Ning Yin; Xu-Ming Mo Journal: PLoS One Date: 2016-01-29 Impact factor: 3.240